Ultime notizie per CVRx (NASDAQ:CVRX) Azioni

CVRx

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

CVRx Inc

News

DoE Selects Consumers Energy To Receive Nearly $20M Financial Assistance Award To Deploy New Technology And Provide Real-time Visibility Into Grid

Apple Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) iPhone 16 scored a win in China in its first three weeks, highlighting the rising demand for luxury smartphones paired with artificial intelligence features. China is a crucial market for the company.
The iPhone 16 performance coincided with China&#8217;s stimulus plans and the upcoming holiday season.
Apple&#8217;s latest smartphone model clocked a sales growth of 20% year-on-year in their first three weeks, beating the iPhone 15, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-10-18/apple-iphone-16-sales-soar-20-in-china-debut-as-demand-recovers?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">cites</a> Counterpoint Research data.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41143369/apple-to-launch-budget-iphone-in-2025-aims-for-market-share-gains-from-huawei-and-xiaomi" rel="noreferrer noopener">Apple To Launch Budget iPhone in 2025, Aims for Market Share Gains from Huawei and Xiaomi</a>
The shift to the premium models fueled sales of the top-end Pro and Pro Max models by 44% year-on-year.
Counterpoint&#8217;s&nbsp;Ivan Lam attributed the iPhone 15&#8217;s weak initial response to production issues and competition from&nbsp;Huawei Technologies Co&#8217;s Mate 60 series.
However, challenges continue to lurk for iPhones from China&#8217;s domestic companies, like&nbsp;Vivo&#8217;s X200 Pro flagship, Huawei&#8217;s next-generation Mate device, and&nbsp;Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) and&nbsp;Oppo&#8217;s upcoming offerings.
Lam also flagged the postponement of purchases by Chinese consumers until November&#8217;s Singles&#8217; Day to avail themselves of discounts from Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)&nbsp;and&nbsp;JD.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>).
Separate reports indicated Chinese online retailers PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) Pinduoduo and Alibaba&#8217;s Taobao doled out discounts on the iPhone 16 series ahead of its official release due to its <a target="_blank" href="https://www.benzinga.com/news/24/09/40785959/iphone-16-fails-to-sway-some-chinese-buyers-im-going-to-buy-huaweis-tri-fold-phone-missing-ai-featur" rel="noreferrer noopener">lack of AI features</a>, which will likely roll out for Chinese users in 2025.
Pinduoduo started selling the iPhone 16 Plus with 512 gigabytes of storage at a 10% discount from the official price. The 128GB iPhone 16 is being sold at an even steeper 11% discount.
Both Pinduoduo and Taobao marketplace have slapped a 4% discount on the 256GB version of the high-end iPhone 16 Pro Max. Tmall shopping platform also offers buyers the option to pay for a new Apple handset in 24 instalments without interest charges.
Kuo Ming-chi of TF International Securities <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3278855/apples-iphone-16-already-selling-discount-china-ai-delay-cools-demand" rel="noreferrer noopener">told</a> SCMP that the global pre-order sales for the iPhone 16 are down 13% compared to last year&#8217;s iPhone 15 launch, partly due to the absence of Apple Intelligence and intense competition in China.
International Data Corporation (IDC)&nbsp;had <a target="_blank" href="https://www.benzinga.com/news/24/08/40600289/apples-market-share-poised-to-gain-genai-and-iphone-16-lead-the-way-idc" rel="noreferrer noopener">projected a recovery</a> in the smartphone market, which was hampered by the supply chain crisis fueled by the 2020 pandemic outbreak in China.
IDC pointed to the success of generative AI in the upcoming iPhone 16 and Apple&#8217;s ability to establish local AI partnerships in China as potential growth factors. It forecasts that GenAI smartphones will capture 18% of the market by 2024, fueled by premium device trends.
Apple stock gained 39% in the last six months. Investors can gain exposure to the stock through Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) and Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
Price Action: AAPL stock traded higher by 1.79% at $236.30 premarket at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41388050/apples-3nm-push-boosts-taiwan-semis-q3-ai-revenue-set-to-triple-analyst" target="_blank" rel="noreferrer noopener">Apple&#8217;s 3nm Push Boosts Taiwan Semi&#8217;s Q3, AI Revenue Set To Triple: Analyst</a></li>
</ul>
Photo courtesy: Apple

Government

Emerging Markets

Tech

Media

AAPL

BABA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XIACF

XIACY

Apple iPhone 16 Sees 20% Sales Surge in China, But AI Absence Prompts Early Price Cuts

HC Wainwright &amp; Co. analyst Sean Lee reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and maintains $7 price target.

Price Target

Reiteration

Analyst Ratings

VSTM

HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $7 Price Target

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) with a Buy and maintains $22 price target.

DCTH

HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $22 Price Target

B of A Securities analyst Vivek Arya maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $165 to $190.

NVDA

B of A Securities Maintains Buy on NVIDIA, Raises Price Target to $190

BMO Capital analyst Fadi Chamoun downgrades Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) from Outperform to Market Perform and lowers the price target from $214 to $210.

Downgrades

ODFL

BMO Capital Downgrades Old Dominion Freight Line to Market Perform, Lowers Price Target to $210

On Friday, CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) appointed longtime executive David Joyner as its new president and CEO, replacing Karen Lynch amid the company&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41398693/cvs-health-appoints-david-joyner-president-and-chief-executive-officer" rel="noreferrer noopener">ongoing financial struggles</a>.
Joyner, previously president of CVS Caremark and an executive vice president at the company, steps into this leadership role as Roger Farah, CVS&#8217;s board chairman, assumes the executive chair position.
The company warned that its upcoming third-quarter earnings, set for release on November 6, will miss Wall Street projections.
The company revealed preliminary third-quarter 2024 adjusted EPS of $1.05-$1.10, compared to the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.70</a>. Analysts expect sales of $92.73 billion.
Results for the third quarter include charges to record premium deficiency reserves (PDRs), primarily related to the company&#8217;s Medicare and Individual Exchange businesses inside its Health Care Benefits segment, of approximately&nbsp;$1.1 billion, which lowered third quarter 2024 Adjusted EPS by&nbsp;$0.63.
In the third quarter of 2024, CVS continued to experience medical cost trends over those projected in its prior outlook.
The Medical Benefit Ratio for the third quarter is currently expected to be approximately 95.2%, which includes a 220-basis point impact from the PDRs.
The company added, &#8221; In light of continued elevated medical cost pressures in the Health Care Benefits segment, investors should no longer rely on the company&#8217;s previous guidance.&#8221;
The pharmacy giant is also backing away from the fiscal year 2024 issued during the second-<a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40220306/cvs-health-reports-mixed-q2-earnings-lowers-2024-outlook-reshuffles-segment-management" rel="noreferrer noopener">quarter earnings release</a>.
The company&nbsp;reported second-quarter sales of $91.23 billion, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $91.51 billion</a>.&nbsp;Adjusted EPS of&nbsp;$1.83&nbsp;decreased from&nbsp;$2.21&nbsp;in the prior year, beating the consensus of $1.73.&nbsp;
In Q2 earnings, CVS Health revised its 2024 adjusted EPS guidance to $6.40-$6.65&nbsp;from at least&nbsp;$7.00&nbsp;versus consensus of $6.98.
CVS Health&nbsp;forecasted&nbsp;2024 sales of $369.0 billion—$372.0 billion versus a consensus of $368.876 billion at prior guidance of at least $369 billion.
The company expected a medical benefits ratio of 90.6% – 90.8% versus ~<a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40220306/cvs-health-reports-mixed-q2-earnings-lowers-2024-outlook-reshuffles-segment-management" rel="noreferrer noopener">89.8% expected earlier</a>.
The company is already struggling as the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health&#8217;s Caremark,&nbsp;Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)&nbsp;Express Scripts, and&nbsp;UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)&nbsp;Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">price of insulin medications</a>.
As per an October report, CVS Health is also considering a major restructuring that could involve separating its&nbsp;retail <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41115344/cvs-health-mulls-split-of-retail-and-insurance-divisions-to-address-financial-challenges-report" rel="noreferrer noopener">and insurance businesses</a>.
These talks with financial advisers explore how a potential breakup would work, although no final decisions have been made yet.
Price Action: At last check on Friday, CVS stock was down 12.30% at $55.87 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41389304/abbott-labs-path-to-double-digit-earnings-growth-in-2025-this-analyst-is-optimistic" target="_blank" rel="noreferrer noopener">Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic</a></li>
</ul>
Image via Shutterstock

Earnings

Large Cap

Guidance

Health Care

Management

Movers

General

Pharmacy Retailer CVS Health Backs Away From Annual Forecast, Names New CEO

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $45 to $80.

CORT

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $80

Baird analyst David Rescott maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Outperform and raises the price target from $503 to $565.

ISRG

Baird Maintains Outperform on Intuitive Surgical, Raises Price Target to $565

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) with a Neutral.

HC Wainwright & Co. Reiterates Neutral on Kezar Life Sciences

AVTR

Avantor Closes Previously Announced Divestiture Of Its Clinical Services Business  In A Transaction Valued At Approximately $650M, Company Sees $500M In After-tax Cash Proceeds And Reduction Of Approximately $50M In Capitalized Leases

SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares are trading higher Friday morning. On Thursday, the company filed a Form RW indicating that it has decided not to <a target="_blank" href="https://ir.sobrsafe.com/sec-filings/all-sec-filings/content/0001477932-24-006541/sobr_rw.htm" rel="noreferrer noopener">proceed </a>with the proposed public offering at this time.
The Commission has not declared the Registration Statement effective, and no securities have been sold in connection with the offering.
Recently, the company announced the pricing of a private placement with institutional investors, expected to<a href="https://www.benzinga.com/news/24/10/41231927/why-sobr-safe-stock-is-getting-hammered" target="_blank" rel="noreferrer noopener"> raise $8.2 million in gross proceeds</a>.
The company planned to issue 2.02 million units at $4.05 per unit, each consisting of one share of common stock or a pre-funded warrant, along with Series A and Series B warrants.
The proceeds were intended to be used for general corporate purposes and working capital. The private placement was expected to close by October 8, pending customary closing conditions.
Price Action: SOBR shares are up 116.3% at $17.20 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41397978" target="_blank" rel="noreferrer noopener">Hedge Fund Billionaire Daniel Loeb Bets On Trump Win, Singles Out This Recent Buy As Having &#8216;Significant Upside Potential&#8217;</a></li>
</ul>

Equities

Small Cap

SOBR

Why Is SOBR Safe Stock Rocketing On Premarket Friday?

Contracts

LASE

Laser Photonics Completes Dual Follow-On Sale To Deliver Two Additional CleanTech Industrial Roughening Laser 3050 Systems To Acuren

VERI

Veritone Enhances Veritone Track To Add Ai-powered Vehicle Tracking; In Addition To Vehicle Tracking, Veritone Track Assists Agencies With Several Other Applications

Manara Minerals, a joint venture between Saudi Arabia's Public Investment Fund (PIF) and Ma'aden (Saudi Arabian Mining Co), is nearing a deal to purchase a 15% to 20% stake in First Quantum Minerals (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FQVLF#OTC">FQVLF</a>) Zambian copper and <a target="_blank" href="https://www.benzinga.com/topic/nickel" rel="noreferrer noopener">nickel assets</a>.
The potential transaction, which Reuters <a target="_blank" href="https://www.reuters.com/markets/deals/saudis-manara-advanced-talks-buy-stake-first-quantums-zambian-mines-2024-10-16/" rel="noreferrer noopener">reported</a> citing information from trusted sources, is valued between $1.5 billion and $2 billion. It includes First Quantum's Kansanshi and Sentinel copper mines and the Enterprise nickel mine.
This deal aligns with Manara's recent investments, including a <a target="_blank" href="https://www.benzinga.com/news/24/10/41311099/terrorism-in-pakistan-threatens-foreign-mine-development-saudi-arabia-still-invests-billions" rel="noreferrer noopener">$1 billion commitment </a>to Barrick Gold's Reko Diq project in Pakistan and a $2.5 billion investment in Brazilian mining giant Vale.
The sale of its Zambian assets would help the company manage its debt while retaining control over its key operations.
In December 2023, after the Panama government <a target="_blank" href="https://www.benzinga.com/markets/commodities/23/12/36259547/copper-shortage-first-quantums-cobre-panama-mine-shuts-down-threatening-supply-balance" rel="noreferrer noopener">ordered the shutdown</a> of its flagship Cobre Panama mine, First Quantum lost significant revenue, pushing the company to <a target="_blank" href="https://www.benzinga.com/markets/commodities/24/03/37483591/first-quantum-exploring-zambian-asset-sales" rel="noreferrer noopener">explore capital restructuring</a>, including selling assets and issuing a $1 billion share offering.
Zambia, a major player in global copper production, holds vast potential for mining investors, as this metal is critical to the green energy transition. This year, B, a startup backed by billionaires including Bill Gates and Jeff Bezos, announced the discovery of one of the <a target="_blank" href="https://www.benzinga.com/news/24/02/36940360/kobold-metals-announces-historic-copper-discovery-in-zambia" rel="noreferrer noopener">largest copper deposits</a> in Zambia's history at the Mingomba site. However, the country's mining sector faces significant challenges, particularly in terms of infrastructure.
Road and rail networks are underdeveloped, limiting material transport, and the country has faced ongoing issues with power supply.
Zambia relies on hydropower for 80% of its electricity, but droughts and fluctuating rainfall have caused frequent shortages.
For companies like First Quantum, ensuring consistent energy for operations has become a key concern. Emergency measures such as importing electricity from South Africa's Eskom have been implemented to mitigate the impact.
Power outages disrupt operations and make mining investments less attractive to foreign investors. The mining industry generates as much as 70% of exports while using about half of the national power demand, making the country's plan to boost the copper output to 1 <a target="_blank" href="https://www.benzinga.com/markets/commodities/24/04/38115830/zambia-mining-boom-the-road-to-1-million-tons-of-copper" rel="noreferrer noopener">million tons by 2026</a> ambitious.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41390144/gold-could-reach-3-000-by-2025-bank-of-america-analyst-says-ultimate-perceived-safe" target="_blank" rel="noreferrer noopener">Gold Could Reach $3,000 By 2025, Bank Of America Analyst Says: ‘Ultimate Perceived Safe Haven'</a></li>
</ul>
Photo via Shutterstock

Rumors

Commodities

FQVLF

GOLD

Saudi Arabia Targeting Billions In Zambian Assets, Despite Persistent Infrastructure Troubles

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $40 price target.

AVXL

HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target

Founded in 1903, SOSS primarily sells its solutions in North American non-residential markets.&nbsp;SOSS will report into the Allegion Americas segment, led by Allegion Senior Vice President Dave Ilardi.

ALLE

Allegion Acquires SOSS Door Hardware; Terms Not Disclosed

American Express Consolidated Provision For Credit Losses $1.4B vs $1.2B A Year Ago

American Express Raises Full-Year EPS Guidance From $13.30-$13.80 To $13.75-$14.05

KSPI

Kaspi.kz Says On Track For FY24 Net Income Growth Of Around 25%

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
CVRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/cvrx-stock-quote/">CVRX</a>) just reported results for the second quarter of 2024.<ul><li>CVRx reported earnings per share of -65 cents. This was below the analyst estimate for EPS of -55 cents.</li><li>The company reported revenue of $11.81 million.</li><li>This was 0.14% better than the analyst estimate for revenue of $11.79 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/07/cvrx-stock-earnings-cvrx-for-q2-of-2024/">CVRX Stock Earnings: CVRx Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CVRX Stock Earnings: CVRx Misses EPS, Beats Revenue for Q2 2024

Piper Sandler Sticks to Their Buy Rating for CVRx (CVRX)

In a report released today, Chase Knickerbocker from Craig-Hallum reiterated a Buy rating on CVRx (CVRX – Research Report), with a price target of ...

Craig-Hallum Sticks to Their Buy Rating for CVRx (CVRX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CVRx (CVRX – Research Report), Adaptive Biotechnolog...

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Adaptive Biotechnologies (ADPT) and Rezolute (RZLT)

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on CVRx (CVRX – Research Report), with a price target of $12.00...

Lake Street Keeps Their Buy Rating on CVRx (CVRX)

Lake Street Remains a Buy on CVRx (CVRX)

CVRx (CVRX) has shared an announcement. CVRx, Inc. bolstered its Board of Directors by appointing Kevin Ballinger and Mitch Hill as new independent...

CVRx Enhances Board with Strategic New Appointments

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on CVRx (CVRX – Research Report) today. The company's shares closed yesterday at $...

CVRx (CVRX) Gets a Buy from Craig-Hallum

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Certara (CERT – Research Report) and CVRx (CVRX – Re...

Analysts Offer Insights on Healthcare Companies: Certara (CERT) and CVRx (CVRX)

Warning: CVRX is at high risk of performing badly

ADPT

CERT

CVRX

RZLT

Legal

Press Releases

CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX

Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the Firm

CVRx Announces Appointment of Two New Board Members

CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024

ARHS

CDLX

AngioDynamics

Accuray

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

BrainsWay Ltd. - American Depositary Shares

BrainsWay

Delcath Systems

Alpha Tau Medical

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

CVRx

Notizie

Ultime notizie per CVRx (NASDAQ:CVRX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO